top of page
  • Active, not recruiting

NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902

Updated: Feb 10

  • BMT CTN 1902

  • NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902


BMT CTN 1902

MM CAR-T to Upgrade Response BMT CTN 1902


This study is designed as a Phase II, multicenter, single arm trial to assess anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptor (CAR) T-cells (bb2121) to improve post autologous hematopoietic cell transplant (HCT) responses among patients with multiple myeloma (MM).


Sponsor

Marcelo Pasquini, MD


Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Blood and Marrow Transplant Clinical Trials Network

National Cancer Institute (NCI)

National Marrow Donor Program

Celgene a wholly owned subsidiary of BMS


Information provided by (Responsible Party)

Marcelo Pasquini, MD, Medical College of Wisconsin


Multiple Locations

 

ClinicalTrials.gov Identifier: NCT02786511


Official Title: Phase II Multicenter Trial of Anti-BCMA CAR T-Cell Therapy for MM Patients With Sub-Optimal Response After Auto HCT and Maintenance Len. BMT CTN 1902


First Posted : September 2, 2021


Click here for details on ClinicalTrials.gov

 
 

Drug: Lenalidomide and bb2121

 

Locations

United States, California

United States, Florida

United States, Illinois

United States, Massachusetts

United States, New York

United States, North Carolina

United States, Pennsylvania

United States, Virginia

United States, Wisconsin


Comments


Commenting has been turned off.
Posts Archive
bottom of page